Introduction and background
Benzene is a commonly used chemical intermediate, employed primarily in the manufacture of other organic chemicals (IARC, 2012) . Benzene occurs naturally in coal and petroleum products, is a by-product of biomass combustion, and is employed in the manufacture of chemicals and drugs (ATSDR, 2007; IARC, 2012) . Inhalation is the major route of exposure as benzene is extremely volatile. Its wide industrial use and potential for exposure to the general public through sources such as cigarette smoke, car exhaust, and refueling, has made benzene a subject of toxicological interest for many decades. Most toxicological studies have focused on the hematopoietic and carcinogenic toxicity of benzene (Khan, 2007) . Benzene is classified as a Group 1 carcinogen with sufficient evidence in both experimental animals and humans that established a causal relationship between high chronic benzene exposure and acute myelogenous leukemia (IARC, 2012) . Extensive human epidemiological and laboratory animal data supports the existence of a functional threshold level of exposure below which adverse health effects would not be expected (Johnson et al., 2009; ECHA, 2018) . However, the mechanism of benzene leukemogenesis is not completely understood and may differ from the mode of action (MoA) by which it might affect reproduction, growth, and development (USEPA, 2002) .
Heightened awareness that some substances may produce effects through endocrine MoAs in humans and wildlife led to the development and implementation of the Endocrine Disruptor Screening Program (EDSP) (USEPA, 2011) . The EDSP is a two-tiered program. Tier 1 evaluates a chemical's potential to interact with the endocrine system in mammals and wildlife. Tier 2 tests for adverse effects in whole organisms and characterizes dose-response (USEPA, 2011). A risk assessment is then performed to determine if the adverse effects identified could occur under foreseeable conditions of exposure to humans and wildlife. A causal link between Tier 1 and 2 cannot be assumed and would require additional evidence. Tier 1 initially comprised eleven screening assays to be evaluated as a battery using weight-of-evidence (WoE) (USEPA, 2011) to determine a chemical's potential to interact with estrogen, androgen, thyroid, and steroidogenesis pathways. In contrast to EDSP, the Organization for Economic Cooperation and Development (OECD) has developed a 5-tiered Conceptual Framework (OECD, 2012) consisting of screens and tests that may support a WoE assessment of impacts on endocrine function. The eleven EDSP screens and Tier 2 tests are found in levels 2 through 5 of the Conceptual Framework along https://doi.org/10.1016/j.yrtph.2018.09.027 Received 11 July 2018; Received in revised form 25 September 2018; Accepted 26 September 2018 with general toxicology and carcinogenicity studies that have less mechanistic specificity but can be relevant and informative in the consideration of endocrine activity (OECD, 2012) .
Benzene is currently among the second list of pesticides and industrial chemicals ("List 2") that may be screened under the EDSP. List 2 currently comprises 109 chemicals selected from an initial list of over 200 candidates that included those pesticides scheduled for Registration Review during fiscal years 2007 and 2008 and those industrial chemicals with a national primary drinking water regulation or those unregulated contaminants listed on the third Contaminant Candidate List (CCL3) (USEPA, 2009) . Since its first use to screen 52 chemicals (List 1) in 2009, the battery has been modified to improve efficiency and reduce the reliance on whole animal testing through the use of high-throughput in vitro assays, in silico methods, and computational models (Browne et al., 2015; Kleinstreuer et al., 2017) . The United States EPA hopes to increase the pace and efficiency of chemical safety assessments by combining the results of these high throughput bioactivity screens with the results of exposure assessment models to prioritize chemicals for endocrine screening (Rotroff et al., 2013) . It seems likely that this process will become standard practice in the future. Because benzene is currently on List 2, we conducted a WoE evaluation of the extant data relevant to hypotheses regarding the potential for benzene to act via estrogen, androgen, thyroid and steroidogenic pathways.
Methods

Literature search
To ensure that this WoE analysis included all relevant information, a systematic literature search strategy was designed that connected the specific chemical name or chemical abstract services (CAS) number to key terms, phrases and search strings related to putative endocrinedisruptive effects, activity via estrogen, androgen, thyroid, and steroidogenic pathways, the specific types of assays used in the EDSP, and general types of toxicity that might be produced by endocrine MoAs (e.g., reproductive toxicity). Searches were conducted in PUBMED and Web of Science, supplemented by searches of governmental literature sources (e.g., ATSDR, NTP, HSDB, DART) to capture literature on endocrine-related cancers and general toxicity endpoints that can be affected via endocrine MoAs. The search was current to October 2017.
The search terms were: endocrine disruption (or disruptor(s)), endocrine effects, toxicity, estrogen(s), estrogenic, anti-estrogenic, estrogen antagonist, androgen(s), androgenic, anti-androgenic, thyroid, hypothyroid, hyperthyroid, anti-thyroid, steroidogen* (* for variations steroidogenesis or steroidogenic), hypothalamic-pituitary (or more specific:HPT axis, (hypothalamic-pituitary-thyroid axis), and HPG axis (hypothalamic-pituitary-gonadal axis). The assay search strings were: (estrogen OR androgen OR (uterine AND cytosol) OR (prostate AND cytosol)) AND receptor AND binding AND assay*, estrogen AND receptor AND alpha AND transcription* AND activation AND assay*, aromatase AND assay, steroidogenesis AND assay, uterotrophic AND assay, Hershberger AND assay, (male OR female) AND pubertal AND assay, male AND intact AND assay, fish AND reproduction AND assay, amphibian AND metamorphosis AND assay, reproductive (associated keywords with truncation for variation: sperm; spermatozoa; spermatogen*; infertility; fertility; ovary, ovaries; ovarian; semen; testic*; testis; testes; gonad*), and developmental (associated keywords with truncation for variation: abnormalities/drug-induced; fetal; foetal; fetus; embryo*; prenatal; terotogen*).
An initial triage of this literature was conducted and the bibliography separated into publications "Apparently Relevant", "Possibly Relevant", or "Apparently Not Relevant". Apparently Relevant and Possibly Relevant studies were reviewed, additional literature identified from the reference lists of those articles, and usable data from relevant studies compiled into tables. Approximately 110 publications and reports were fully reviewed.
Data quality assessment
Data selected for testing the MoA hypotheses were evaluated according to their primary, secondary, and tertiary validity as recommended previously (Borgert et al., 2011a, Supplemental Material) , which is consistent with the U.S. EPA's guidance on data quality assessment (USEPA, 2011) . Primary validity (the identity and integrity of the measurements) was assumed for studies conducted according to international (e.g., OECD; USEPA) toxicological guidelines and for studies reported in the peer-reviewed literature that employed similar measurement techniques (Borgert et al., 2016) . Secondary validity (adequate controls and the reliability of the recorded measurements) was evaluated by subjecting each study to the methods of Klimisch et al. (1997) via the ToxRTool created by the European Center for the Validation of Alternative Methods (Schneider et al., 2009) . A Klimisch score of 1-3 was assigned to each study based on the adequacy and reliability of the study methods and reporting. Studies that achieved Klimisch scores of 1 (reliable) and 2 (reliable with certain restrictions), were used for the WoE analysis. Studies given a Klimisch scores of 3 (not reliable) were not included in the WoE analysis but were considered nonetheless, and are discussed in text, as needed, or in Appendix A. Tertiary validity (probative nature of the study design for evidence of causation) was evaluated according to the ability of the study to provide a causal link between the endpoint measured and the hypothesized MoA.
Weight-of-evidence methodology
The methodology used for this WoE analysis is based on the approach of Borgert et al. (2011a; , which was developed to evaluate results of the U.S. EPA's EDSP Tier 1 screening assays. This approach defines specific hypotheses related to interactions with estrogen, androgen, thyroid, and steroidogenic pathways, and weights the importance of endpoints as Rank 1, 2, or 3 according to their mechanistic relevance for each hypothesized MoA. It then applies an interpretive algorithm that sequentially considers responses produced by a chemical in Rank 1, 2, and 3 endpoints, in order of their importance for evaluating the hypothesis.
The weighting scheme and interpretive algorithm used herein follows the same logic but was adapted to accommodate long-term toxicity tests. Adaptations are necessary because the intent and design of toxicity testing differs greatly from endocrine screening. Toxicity tests evaluate apical endpoints intended to reflect adverse effects, irrespective of the MoA that produces the adverse effect, whereas endocrine screening assays measure endpoints intended to reflect interaction with a very specific pathway within the endocrine system irrespective of whether that interaction portends adverse effects. Results of screening assays cannot determine whether a chemical has endocrine disruptive properties because they do not identify adverse effects. According to the World Health Organization/International Programme on Chemical Safety definition, endocrine disruptive properties are identified when the mode(s) of endocrine activity identified in endocrine screens are In keeping with their purpose as mechanistic screening assays, several endpoints evaluated in the U.S. EPA EDSP were assigned a Rank 1 relevance, meaning that they are "… specific and sensitive for the hypothesis, are interpretable without knowing the response of other endpoints, and are in vivo measurements rarely confounded by artifacts or non-specific activity" (Borgert et al., 2014) . However, no endpoint measured in toxicity tests with benzene achieves such a high level of mechanistic specificity for an endocrine-mediated effect, and hence, none are assigned to the Rank 1 category. Endpoints measured in toxicity tests were assigned to relevance Ranks 2 and 3 according to their specificity for the particular MoA hypothesis. Rank 2 endpoints are similar to Rank 1 endpoints except that they are less informative as they may be subject to confounding influences that make interpretation difficult. Rank 3 endpoints are only corroborative of other endpoint responses in the overall WoE but cannot be used alone to support a hypothesis (Borgert et al., 2014) .
Nonetheless, a general principal of endocrine screening and testing is that the results of in vivo tests supersede the results of screening assays (EDSTAC, 1998; USEPA, 2011; Borgert et al., 2011b ) because a potential endocrine MoA (i.e., a potential for endocrine activity in vivo)
is meaningless unless the chemical produces an adverse effect via that activity. Thus, a lack of response in toxicity endpoints is a strong indication that the chemical lacks endocrine disruptive properties, but an observed response is ambiguous because these tests measure apical endpoints that can be affected by both endocrine and non-endocrine MoAs. Positive results in toxicity tests cannot be assumed to reflect endocrine disruptive properties unless a causal linkage is made to an underlying endocrine MoA. A second general principle of endocrine screening and testing is that no single assay or endpoint should be considered in isolation. Hence, this WoE evaluation considered whether benzene produces a pattern of adverse effects consistent with agonist or antagonist activity via estrogen, androgen, or thyroid pathways, or consistent with induction or inhibition of steroidogenic enzymes. Although complete consistency of response across all endpoints relevant for a particular MoA might occur only with a highly potent prototype chemical (e.g., ethinyl estradiol for the estrogen agonist MoA), this would not be required for inferring potential endocrine activity. However, a preponderance of negative responses among the relevant endpoints would suggest the absence of activity, especially when the pattern is inconsistent among different studies of similar design. Note: The endpoint response for a study marked {} are noted by the following symbols: increase (↑), decrease (↓), or Δ (change, compared to control). Sex is noted (female ♀) when response is sex specific. All studies marked [ ] had no effects for the endpoint. Species tested are noted by the following symbols: rat (r), mouse (m), rabbit (rb). * Effect occurred at a dose that resulted in a significant reduction in body weight gain compared to controls. Tables 1-4 summarize the data used in the WoE analysis for each of the eight hypotheses. The types of studies conducted with benzene that are relevant for an assessment of impacts on endocrine function are all Tier 2-like or OECD Conceptual Framework level 4 and 5 studies that measure apical endpoints. As such, these endpoints were categorized as relevance ranks 2 or 3, because they could be affected by both endocrine-related and non-endocrine MoAs. In assigning ranks to the endpoints, consideration was given to how well the data informed the specific hypothesis being tested, and if literature was found that established the ability of the endpoint to address the hypothesis. The relevance rankings assigned in this evaluation are subject to future modification should additional data be developed regarding their relevance for testing hypotheses about endocrine MoA.
Results
Benzene has also been evaluated in U.S. EPA's ToxCast™ program, which is a collection of high-throughput assays in living cells or isolated proteins used to screen chemicals for many different types of biological activity. The U.S. EPA is currently using a subset of the ToxCast™ assays to prioritize chemicals for evaluation under the EDSP. There was no indication of activity among the ToxCast™ assay runs targeted for endocrine pathways, including assays for in vitro estrogen receptor agonist and antagonist activity, in vitro androgen receptor agonist and antagonist activity, in vitro thyroid receptor agonist and antagonist activity, and in vitro aromatase inhibition activity (see Appendix B). However, there were also no indications of activity in the assays in the larger ToxCast™ library of assays targeting many different potential MoA, suggesting a possibility of false negative responses, likely due to the volatility of benzene in the test system.
Estrogen agonist hypothesis
Fourteen studies were found that report endpoints relevant to the hypothesis that benzene interacts as an agonist or antagonist with components of estrogen pathways (Table 1) .
Hormone-dependent reproductive organ weights and histopathology are sensitive to estrogen agonists and or antagonists. For example, estrogen agonists induce atrophy and reduce the weight of testes (Cook et al., 1998) , while estrogen antagonists induce atrophy and reduce the weight of ovaries and uterus (Ashby et al., 2002; Note: The endpoint response for a study marked {} are noted by the following symbols: increase (↑), decrease (↓), or Δ (change, compared to control). Sex is noted (female ♀) when response is sex specific. All studies marked [ ] had no effects for the endpoint. Species tested are noted by the following symbols: rat (r), mouse (m), rabbit (rb). * Effect occurred at a dose that resulted in a significant reduction in body weight gain compared to controls.
et al., 2014). Ovary and uterus weights were not reported in the reproductive or repeat dose studies (Table 1) although five studies reported histopathology for mammary gland, uterus, and ovary. Other apical reproductive and developmental endpoints from studies with benzene are available to contribute to the WoE assessment, although they are considered as rank 3 endpoints as they cannot be used alone to distinguish between direct or indirect involvement with the endocrine system. Adult and pup testes weight and histopathology, rank 2 endpoints, were assessed in repeat dose and reproductive toxicity studies with benzene. In the study by Kuna et al. (1992) , where female rats were exposed by inhalation for 10 weeks prior to mating and throughout mating, gestation, and lactation, there were no changes noted in pup testes weight. Adult testes weight was also assessed in two repeat-dose toxicity studies with mice and rats. In a 13-week subchronic inhalation study by Ward et al. (1985) , testes weights were reduced at the highest dose tested (300 ppm) compared to controls in CD-1 mice, but there were no effects on testes weight in the same study with Sprague-Dawley rats. Similarly, there were no changes in rat testes weight in a 14-day gavage study, even at the highest dose that resulted in 100% mortality .
There were no changes in testis and epididymis histopathology in a 10-week dominant lethal study in rats (Biodynamics, 1980) , in a twoyear carcinogenesis study in both mice and rats performed by the National Toxicology Program (NTP, 1986) or in a 27-week carcinogenesis study in mice (NTP, 2007) . Testis atrophy was increased in mice, but not rats, in a study by Ward et al. (1985) . Singh and Bansode (2011) reported degenerative changes in the testis, occurring at doses that resulted in signs of overt toxicity and a reduction in food intake.
No changes in uterine histopathology were observed in either mice or rats (Table 1) , although ovarian and mammary gland tumors and ovarian cysts were noted in two studies in mice NTP, 1986) . With respect to the mammary gland tumors, no similar pathology or changes in non-neoplastic lesions were found in rats of either sex or in male mice (NTP, 1986) or in either sex in a 27-week study in mice (NTP, 2007) . The ovarian cysts noted in the study by Ward et al. (1985) were at a dose where reductions in weight gain and mortality occurred. Epididymal sperm count was reduced in rats, but at a dose that was overtly toxic , and in mice but not rats in the study by Ward et al. (1985) . Epididymal histopathology was not assessed in either of these studies. The majority of the endpoints evaluated in these higher-tiered chronic studies fall into the rank 3 designation. There were no effects on reproductive endpoints, including mating, fertility, gestational length, pre-and post-implantation loss, litter size, pup survival, or pup sex ratio in reproduction studies in rats (Biodynamics, 1980; Kuna et al., 1992) .
None of the available developmental/teratogenicity studies with benzene were specifically designed to investigate an endocrine MoA, as they did not begin dosing until after implantation was complete and sex was determined. The primary endpoints potentially relevant for a WoE evaluation are post-implantation loss and an evaluation of gonads in the pups, if performed. There were no impacts on post-implantation loss in mice, rats, or rabbits in eight studies evaluating the developmental toxicity of benzene (Table 1) .
Overall, the lack of responses in estrogen-sensitive reproductive tissues and with no impacts on reproduction and development, including pup sex ratio, suggest that benzene is not acting as an estrogen agonist or antagonist. Note: The endpoint response for a study marked {} are noted by the following symbols: increase (↑), decrease (↓), or Δ (change, compared to control). Sex is noted (female ♀) when response is sex specific. All studies marked [ ] had no effects for the endpoint. Species tested are noted by the following symbols: rat (r), mouse (m), rabbit (rb).
Reference numbers refer to the following studies.
* Effect occurred at a dose that resulted in a significant reduction in body weight gain compared to controls.
Interaction with the androgen pathway
The same 14 studies that reported on endpoints sensitive to the estrogen pathway also provide endpoints that are relevant to an assessment of potential interactions with the androgen pathway.
An androgen agonist would be expected to increase the weights of androgen-dependent tissues in males, while a decrease in weights would be expected with an androgen antagonist. Androgen-dependent tissues assessed in some of the studies with benzene include testis, seminal vesicles, epididymis, and prostate. Mating and fertility indices, pup survival, and sex ratio are also endpoints that are relevant for assessing interaction with the androgen pathway, although these are generally corroborative, rank 3 endpoints as they can be impacted by multiple MoA, as well as systemic toxicity.
There were no studies where androgen-sensitive organ weights were increased with benzene exposure (Table 2 ). There were also no impacts on mating or fertility indices, pre-or post-implantation loss or sex ratio when these endpoints were assessed in the two reproductive toxicity studies and eight development toxicity studies with mice, rats, or rabbits exposed to benzene. There was an increase in post-implantation loss, in two of ten developmental toxicity studies, both occurring at doses that resulted in reduced maternal body weight gain . There were no changes in pup testis weight in the reproduction study by Kuna et al. (1992) , an indication that benzene did not impact the androgen-sensitive developing male reproductive system. Testis weight and sperm count were decreased and testis atrophy increased in one study in mice , and changes in testis histopathology were observed in one of three studies in rats ( Table 2 ). The increase in testis atrophy in rats, along with a decrease in seminal vesicle weight in the study by Singh and Bansode (2011) , occurred at doses that resulted in a reduction in food intake and signs of overt toxicity. The only other differences compared to controls were in the rank 3 endpoints of histopathological changes in the female mammary gland and ovary, in one and two studies in mice, respectively, and in the uterus in one study in rats.
The available evidence indicates a lack of potential for benzene to demonstrate either an androgenic or anti-androgenic MoA. Whereas positive results could be due to either an endocrine or a non-endocrine MoA, the interpretation of negative results from multiple studies clearly indicates a lack of endocrine-specific activity. Note: The endpoint response for a study marked {} are noted by the following symbols: increase (↑), decrease (↓), or Δ (change, compared to control). Sex is noted (female ♀) when response is sex specific. All studies marked [ ] had no effects for the endpoint. Species tested are noted by the following symbols: rat (r), mouse (m), rabbit (rb). * Effect occurred at a dose that resulted in a significant reduction in body weight gain compared to controls.
Interaction with the hypothalamic-pituitary-thyroid axis
In the WoE framework (Borgert et al., 2014) , thyroid hormones, along with thyroid weight and histopathology, are considered together in the assessment of agonist or antagonist activity. While thyroid antagonists typically cause follicular cell hypertrophy/hyperplasia and an increase in thyroid gland weight (Marty et al., 2001a) , agonists may or may not impact thyroid weight and histopathology. There were no studies with benzene that evaluated thyroid hormone levels in conjunction with thyroid histopathology. Given that, it would be difficult to conclude if benzene was acting as an agonist or antagonist, as the directionality of hormone changes is not known.
While a number of studies with benzene claim to have measured thyroid weights, only the repeat-dose study by Ward et al. (1985) reported results for this endpoint (Table 3 ). In the 13-week subchronic inhalation study with rats, absolute and relative thyroid weights were increased in the mid-dose group females and only in animals sacrificed after 14 days of exposure when compared to controls. Since the increase in thyroid weight occurred at only one of six sampling timepoints, with no changes in thyroid weight noted in either sex at any other dose or time during the study, it is unlikely that the day 14 response at one dose level was exposure related. In addition, no changes in thyroid histopathology in mice or rats have been reported (NTP, 1986; 2007; Ward et al., 1985) .
Impacts on growth are also rank 2 endpoints for the thyroid antagonist hypothesis. A reduction in fetal weight is a consistent response in developmental toxicity studies with benzene across multiple species (Table 3) . Only one study in rabbits reported no change in fetal weight compared to controls . Pup weight was also reduced in one of two reproduction studies, but only in females and only at the day 21 timepoint (Table 3) . There was an increase in post-implantation loss in two of ten developmental toxicity studies, both occurring at doses that resulted in reduced maternal body weight gain . There were no changes in post-implantation loss in the two rat reproductive toxicity studies (Biodynamics, 1980; Kuna et al., 1992) .
Pituitary gland hypertrophy/hyperplasia often co-occur with similar changes in the thyroid gland when exposed to thyroid-active substances (Mellert et al., 2003) . Pituitary weight and histopathology, along with liver weight, were assessed in studies by NTP (1986 NTP ( , 2007 and Ward et al. (1985) . No changes in weight or histopathology were noted in either mice or rats, except for a decrease in liver weight in mice (Table 3 ). In addition, there were no impacts on liver or testes weight or pup survival in reproduction studies in rats (Table 3) .
Overall, there are no consistent findings in the studies with benzene suggesting an adverse effect on the hypothalamic-pituitary-thyroid (HPT) axis.
Interaction with the steroidogenic pathway
The steroidogenic pathway hypothesis is focused on testing if benzene interferes with steroid hormone synthesis. Given the hematological focus of most studies with benzene, no data on steroid hormone concentrations or aromatase activity were identified. However, similar to the estrogen and androgen hypotheses, adverse effects on reproduction (e.g., mating, fertility) and changes to reproductive organ weights and histopathology are relevant endpoints in the WoE for interactions with steroidogenesis. Decreases in the weight of seminal vesicles, prostate, and epididymides have been observed in studies with chemicals that inhibit aromatase and steroid biosynthesis (Marty et al., 2001b; O'Connor et al., 2002) . Compounds that interact with the steroidogenic pathway could also alter adrenal gland weight and histopathology (Stoker and Zorrilla, 2010) .
Of the 15 endpoints designated as rank 2, the only effects noted were a decrease in testis weight in two studies in mice, one of which cooccurred with decreased maternal weight gain, and testis atrophy and adrenal hyperplasia noted in one study each in rats and mice (Table 4) . The increase in adrenal hyperplasia in mice occurred only in the middose in males and the high dose in females, while the increase in rats only occurred at the low dose of each sex (NTP, 1986) . No changes in adrenal histopathology were noted in two other studies in mice and one in rats NTP, 2007) covering the same dose range as that in the NTP study.
In the rank 3 endpoints, there was an increase in post-implantation loss in one developmental toxicity study with rats and one with rabbits, both occurring at doses that resulted in reduced maternal body weight gain (Table 4) . Increases in post-implantation loss in two of ten studies and at maternally toxic doses, with inconsistent changes in mammary gland and ovarian histopathology, seminal vesicle weight, and sperm count in a few repeat-dose studies (Table 4) , do not provide substantive evidence of adverse effects caused by changes in steroid hormone concentrations.
Although no direct measurements of steroid hormone concentrations were found in studies with benzene, the results from multiple developmental, reproduction, and carcinogenicity studies evaluating endpoints relevant for an assessment of the hypothalamic-pituitarygonadal axis, including steroidogenesis, suggest that it is unlikely that benzene is inducing or inhibiting steroidogenesis.
Discussion
It must be recognized that the reproductive and developmental toxicity of benzene was characterized for the most part prior to recent changes in regulatory testing guidelines directed at increasing their ability to identify endocrine-mediated adverse effects. For example, additional endpoints were added to the reproduction study guidelines to increase the mechanistic specificity of the study (USEPA, 1998) . It is theoretically possible, but highly unlikely, that adverse effects due to an endocrine activity of benzene were unidentified in reproduction studies conducted prior to these changes. To this point, a recent comprehensive analysis of the multi-generation studies indicates that the multi-generation reproduction studies are generally less sensitive than the chronic 2-year study and comparable in sensitivity to the 90-day study (Martin et al., 2009) . Even though benzene has not been evaluated using the updated reproduction protocol, it has been evaluated in all three types of studies and it, therefore, seems unlikely that adverse endocrine-mediated effects have been overlooked.
Exposure to benzene can result in responses in some endocrinesensitive tissues, such as testis and ovary, along with a reduction in fetal weight, in OECD level 4 and 5 repeat-dose and developmental toxicity studies. However, an endocrine MoA for these effects is highly unlikely for several reasons. In order of increasing importance: there is inconsistency in the adverse effects observed in different studies; there is inconsistency in the pattern of effects elicited by benzene versus patterns of effects that would be expected were benzene to work via estrogen, androgen, thyroid or steroidogenic MoAs; and other MoAs are likely responsible for the effects of benzene on endocrine-sensitive tissues.
With respect to the involvement of other MoAs, EPA (USEPA, 2002) has reviewed the reproductive and developmental effects of benzene, but endocrine MoAs are not among the possible explanations for those effects. Instead, the proposed MoAs are high-dosage effects on several physiological and biochemical targets. The effect of benzene may arise due to reduced ascorbic acid content in the fetus and in maternal organs, an effect that appears first in maternal liver and later in placenta and fetal liver. Via this postulated MoA, benzene's effects on endocrinesensitive tissues occurs as a tertiary effect of reduced fetal ascorbic acid levels, which is itself secondary to decreased maternal levels. A second postulated MoA is an effect on nucleotide content in placenta and fetal liver (increased DNA and reduced RNA) and maternal liver (decreased DNA). A third proposed MoA is damage to peripheral adrenergic nerve fibers, which disturbs the control of ovarian blood flow and reduces uterine steroid hormone production, ultimately leading to embryotoxicity. Other postulated MoAs include direct toxicity to the embryonal cells, direct toxicity to fetal bone marrow and testicular tissue, or, fetal toxicity from impaired nutritional status secondary to adverse effects on maternal circulation Keller and Snyder, 1986) . A recent review also fails to propose endocrine MoAs for the effects of benzene and related chemicals on female reproduction (Sirotkin and Harrath, 2017) .
Chemicals with estrogenic and anti-androgenic MoA and those that impact steroidogenesis often affect events early in pregnancy, including decreased ovulation, reduced fertility, and increases in pre-and postimplantation loss (Zhao et al., 2013 (Zhao et al., , 2014 . Benzene has been evaluated in a number of developmental studies, as well as in a reproduction study that targeted exposures from pre-mating through lactation. The only consistent adverse response seen at doses that are not maternally toxic is a reduction in fetal weight compared to controls (Table 3) , often with accompanying delays in ossification.
The interpretation of delayed ossification must account for important distinctions and confounding conditions (DeSesso and Scialli, 2018) . Delayed ossification is not a structural abnormality (Makris et al., 2009) and is potentially associated with fetal weight reduction and/or maternal toxicity (typically defined as mortality or a reduction in the rate of maternal weight gain during pregnancy of 10% or greater, or clinical signs, such as sedation). In reporting the deliberations of a Teratology Association Working Group, Guittin et al. (2000) discounted the importance of delayed ossification when coincident with fetal weight gain deficits or maternal toxicity. Carney and Kimmel (2007) explain that delayed ossification has no general predictive value for teratogenicity and typically reflects a delay in growth that subsequently catches up in the early postnatal period and includes complete ossification. Its transient nature is particularly likely when reduced ossification is restricted to bones that normally ossify late in gestation, e.g., sternebrae 5 and 6, phalanges, centra of the thoracic, sacral and caudal vertebrae, and calvaria. Under such circumstances, delayed ossification produces no adverse consequences.
Benzene health impacts have been evaluated in a number of epidemiology studies, however none of the available studies have specifically evaluated effects on the endocrine system. The few studies that have evaluated the potential effects of benzene on fertility, reproduction, or development are inconclusive due to many deficiencies, including poor study designs, problems in identifying exposed populations, a lack of data on exposure levels, and/or concurrent exposure to multiple substances (USEPA, 2002; EU, 2008) . The majority of the epidemiological data available focuses on the hematopoietic responses after exposure to benzene, with lymphopenia being the most sensitive response of humans to chronic exposure (EU, 2008) .
There were no studies with wildlife that were deemed appropriate for inclusion in the endpoint tables (Tables 1-4) , although a few studies with aquatic biota can be considered as a line of evidence in the WoE assessment. Russom and Broderius (1991) studied the toxicity of benzene in an early life stage test with fathead minnow (Pimephales promelas). Endpoints in the early life-stage study such as hatching success, time to hatch, length, weight, and behavior are relevant for an assessment of the HPG axis in fish as developmental delays or anomalies may result from perturbations of the endocrine system. However, caution is advised in the interpretation of such changes as adverse effects could be mediated via multiple MoAs. In the study by Russom and Broderius (1991) the most sensitive endpoint reported was a low effect concentration of 1.6 mg/L for growth (wet weight and length). This value was the most conservative reliable chronic endpoint for freshwater fish identified in the EU risk assessment (EU, 2008) . Interestingly, the acute 50% lethal concentration (LC50) value for benzene is reported as 5.3 mg/L for rainbow trout (Oncorhynchus mykiss) (DeGraeve et al., 1982) which is very close to the lowest observable effect concentration from this early life-stage study, suggesting that the mechanism of action is narcotic and not a more subtle endocrine effect.
Conclusion
The database relevant for an assessment of the potential for benzene to interact with the endocrine system consists predominately of chronic studies evaluating reproduction, growth, and development. Although mechanistic data is often needed to establish a causal link between a potential endocrine MoA and observed adverse effects, consistent observations supporting a specific hypothesis (e.g., estrogen agonist, thyroid antagonist) in multiple studies can be used to draw conclusions for or against a particular MoA hypothesis. While there were responses in a few studies on reproductive organ weights and histopathology, there were no consistent patterns of effects that would suggest that benzene has endocrine activity. Based on an evaluation of all relevant data from multiple animal species, this hypothesis-testing WoE assessment reveals that benzene is not acting as an agonist or antagonist with the estrogen, androgen, thyroid, or steroidogenesis pathways.
